title: Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells.
abstract: Amplification and overexpression of the E2F3 gene at 6p22 in human bladder cancer is associated with increased tumour stage, grade and proliferation index, and in prostate cancer E2F3 overexpression is linked to tumour aggressiveness. We first used small interfering RNA technology to confirm the potential importance of E2F3 overexpression in bladder cancer development. Knockdown of E2F3 expression in bladder cells containing the 6p22 amplicon strongly reduced the extent of bromodeoxyuridine (BrdU) incorporation and the rate of cellular proliferation. In contrast, knockdown of CDKAL1/FLJ20342, another proposed oncogene, from this amplicon had no effect. Expression cDNA microarray analysis on bladder cancer cells following E2F3 knockdown was then used to identify genes regulated by E2F3, leading to the identification of known E2F3 targets such as Cyclin A and CDC2 and novel targets including pituitary tumour transforming gene 1, Polo-like kinase 1 (PLK1) and Caveolin-2. For both bladder and prostate cancer, we have proposed that E2F3 protein overexpression may cooperate with removal of the E2F inhibitor retinoblastoma tumor suppressor protein (pRB) to drive cellular proliferation. In support of this model, we found that ectopic expression of E2F3a enhanced the BrdU incorporation, a marker of cellular proliferation rate, of prostate cancer DU145 cells, which lack pRB, but had no effect on the proliferation rate of PC3 prostate cancer cells that express wild-type pRB. BrdU incorporation in PC3 cells could, however, be increased by overexpressing E2F3a in cells depleted of pRB. When taken together, these observations indicate that E2F3 levels have a critical role in modifying cellular proliferation rate in human bladder and prostate cancer.
authors.affiliation: Section of Molecular Carcinogenesis, Institute of Cancer Research, Male Urological Cancer Research Centre, Sutton, Surrey, UK. yvonne.olsson@icr.ac.uk
authors.forename: A Y
authors.initials: AY
authors.lastname: Olsson
authors.forename: A
authors.initials: A
authors.lastname: Feber
authors.forename: S
authors.initials: S
authors.lastname: Edwards
authors.forename: R
authors.initials: R
authors.lastname: Te Poele
authors.forename: I
authors.initials: I
authors.lastname: Giddings
authors.forename: S
authors.initials: S
authors.lastname: Merson
authors.forename: C S
authors.initials: CS
authors.lastname: Cooper
mesh_terms: D045744:Cell Line, Tumor; D049109:Cell Proliferation; D050699:E2F3 Transcription Factor / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D001749:Urinary Bladder Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*
chemical_list: D050699:E2F3 Transcription Factor; C098319:E2F3 protein, human